Journal
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
Volume 86, Issue 2, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/mmbr.00159-21
Keywords
Staphylococcus aureus; MRSA; MecA; antimicrobial resistance
Categories
Funding
- UKRI Strategic Priorities Fund [EP/T002778/1]
- EPSRC [EP/T002778/1] Funding Source: UKRI
Ask authors/readers for more resources
The development of resistance to beta-lactam antibiotics has made Staphylococcus aureus, especially MRSA, a global clinical burden. The acquisition of mecA, which encodes PBP2A, allows MRSA to proliferate in the presence of beta-lactams. Further genetic adjustments are required to develop high-level resistance.
The development of resistance to beta-lactam antibiotics has made Staphylococcus aureus a clinical burden on a global scale. MRSA (methicillin-resistant S. aureus) is commonly known as a superbug. The development of resistance to beta-lactam antibiotics has made Staphylococcus aureus a clinical burden on a global scale. MRSA (methicillin-resistant S. aureus) is commonly known as a superbug. The ability of MRSA to proliferate in the presence of beta-lactams is attributed to the acquisition of mecA, which encodes the alternative penicillin binding protein, PBP2A, which is insensitive to the antibiotics. Most MRSA isolates exhibit low-level beta-lactam resistance, whereby additional genetic adjustments are required to develop high-level resistance. Although several genetic factors that potentiate or are required for high-level resistance have been identified, how these interact at the mechanistic level has remained elusive. Here, we discuss the development of resistance and assess the role of the associated components in tailoring physiology to accommodate incoming mecA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available